Osseopulsebrs

Biolux Research announces completion of successful new clinical study for light-accelerated implantology

July 29, 2013
Biolux Research Ltd. announces the successful completion of a new clinical study using a shorter, more efficient, photobiomodulation treatment protocol to increase implant stability after surgery.

Biolux Research Ltd. is pleased to announce the successful completion of a new clinical study using a shorter, more efficient, photobiomodulation treatment protocol to increase implant stability after surgery.

RELATED |Fluoride treatment of synthetic biomaterial assists dental bone regeneration

The clinical study was recently completed at the University of Toronto (Canada) by Mr. Mahdi Ghuloom, as part of his Master of Science thesis in the Graduate Department of Dentistry. The study investigated the efficacy of a new treatment protocol for the OsseoPulse™, Biolux’s approved photobiomodulation product, on implant stability. The new treatment protocol consists of a preoperative 20-minute phototherapy session on the day of surgery, followed by daily phototherapy sessions for the next 10 days, compared to the original 21-day treatment protocol). The results of the study show an increase in implant stability starting from day zero for the treated group, compared to the typical decrease in implant stability in the first few weeks after placement, as shown in the control group. The increase in implant stability with the new protocol suggests a reduced risk of implant failure and the potential for earlier or immediate loading of implants.

RELATED |Less invasive approach to dental implants allows heart patients to continue anticoagulation therapy

“We believe that the significantly shorter protocol will lead to greater patient interest and compliance with the OsseoPulse™ treatment, resulting in better implant success for the patient” states Dr. Peter Brawn, founder and Chief Scientific Officer of Biolux. “Dentists will also benefit from a 10-day protocol by treating more patients with a shorter turnaround time per device as well as continuing to differentiate their practice.”

The new treatment protocol has received regulatory approval from Health Canada and European CE Mark, and is supported by devices already on the market as the dentist can simply prescribe a shorter duration treatment for the patient.

Multiple marketing materials were updated to reflect the advancements made over the past year in accelerating implantology using the OsseoPulse™ Bone Regeneration System. The materials are now available on the Biolux website at bioluxresearch.com/dentist.htm.



About Biolux Research
Biolux Research Ltd. is a world leader in the development of light activated bone regeneration systems for dentistry. Biolux focuses on product development, clinical and basic research, and its proprietary, patent-pending OsseoPulse™ Bone Regeneration System is premised on a vision to transform the practice of implantology and oral surgery in dentistry by accelerating implant integration and bone regeneration in a safe, effective, and noninvasive approach.